Skip to main content
OpenTrials
Completed

NCT Number: NCT00460226

Lamictal Bipolar Observational Study

This is multi-center, prospective, observational stud. This study is designed to evaluate the rate of non-serious rash in Korean bipolar I patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply:
  • Provides written informed consent
  • Male or female age 18 years or older A female subject is eligible to enter and participate in the study if she is of;
  • Non-childbearing potential
  • Childbearing potential, has a negative pregnancy test at screen
  • Diagnosis of bipolar I disorder using DSM-IV criteria

Exclusion criteria

  • A subject will not be eligible for inclusion in this study if any of the following criteria apply:
  • Previous or current treatment with lamotrigine
  • Presence of a clinically significant psychiatric or physiologic comorbidity, including significant substance abuse, severe depression or mania which is of an unstable or progressive nature that could, in the opinion of the investigator, interfere with participation in this study
  • Presence of untreated thyroid disease
  • Have active suicidality or homicidality, history of recent suicide attempts within the past year, or, in the investigator's opinion, a marked risk for suicide
  • History of severe hepatic or renal insufficiency or significant hematologic disease or other significant medical or psychiatric condition that would interfere with subjects' participation in the study
  • Currently participating in another clinical trial, or plans to enroll in another trial while participating in this study
  • Currently pregnant or is breastfeeding

Treatment and study plan

Lamotrigine

Drug

lamotrigine treatment for 12weeks

Primary outcomes

  1. Occurrence of non-serious rash during 12 weeks of treatment with lamotrigine in patients with bipolar I in Korea

    Time frame: 12 weeks

Secondary outcomes

  1. CGI-BP at Week 12 and occurrence of adverse events at Week 12

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Apr 13, 2007
Registry last updated
Mar 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.